Background. The CD4 T cell count recovery in human immunodeficiency virus type 1 (HIV-1)-infected individuals receiving potent antiretroviral therapy (ART) shows high variability. We studied the determinants and the clinical relevance of incomplete CD4 T cell restoration.
consists of a durable suppression of viral replication, a steep increase in the CD4 T cell count, and a partial reversal of HIV-1-associated immunological alterations [1] [2] [3] [4] [5] [6] [7] . A complete and durable restoration of the CD4 T cell count and, particularly, of critical T cell subsets, such as naive cells, can be best achieved by very early initiation of ART, preferably during primary HIV-1 in fection [8, 9] . In chronic HIV-1 infection, the recovery of the CD4 T cell count is hindered by residual viral replication, impaired thymic function, advanced age, enhanced T cell activation and apoptosis, and, possibly, viral coinfection [7, [10] [11] [12] [13] . As a consequence, a substantial proportion of treated individuals show incomplete or even poor CD4 T cell recovery [6, 14] . In some studies, CD4 T cell counts seemed to reach a plateau after the first 2-3 years of ART [7, 15, 16] , whereas other studies found that, for selected groups of patients with a well-suppressed HIV-1 RNA load, there were continuous, albeit small increases in CD4 T cell counts even after 3-4 years of ART [11, 17] . Thus, long-term CD4 T cell recovery, including its modulating factors, needs further evaluation.
In this study, we addressed 3 important issues. First, we analyzed CD4 T cell and CD8 T cell counts during a minimum observation period of 5 years in a large, highly selected cohort of 293 HIV-1-infected individuals with continuously suppressed plasma HIV-1 RNA load, to characterize individual patterns of CD4 T cell recovery. Second, we evaluated the clinical relevance of incomplete CD4 T cell recovery to !500 cells/ mL. Third, we studied potential determinants of CD4 T cell recovery, with the goal of predicting CD4 T cell responses during the first months of ART. We hypothesized that advanced immunodeficiency would limit CD4 T cell recovery and that CD4 T cell kinetics before initiation of ART might predict of the magnitude of CD4 T cell recovery during ART [7] . 
METHODS

Study design.
We studied longitudinal CD4 T cell counts, CD8 T cell counts, and plasma HIV-1 RNA levels in 293 treatment-naive, HIV-1-infected persons in the Swiss HIV Cohort Study up to 4 years before and during a minimum follow-up period of 5 years after initiation of ART. Laboratory data were collected every 3-6 months. ART was defined as a combination of at least 3 antiretroviral drugs, including either 2 nucleoside analogue reverse-transcriptase inhibitors (NRTIs) in combination with a protease inhibitor or a non-NRTI (NNRTI), 2 protease inhibitors in combination with at least 1 NRTI, a combination of a protease inhibitor and an NNRTI with at least 1 NRTI, or a combination of 3 NRTIs.
Because the objective was to study the maximum regenerative capacity of the immune system, the analysis was restricted to patients who achieved and maintained plasma HIV-1 RNA loads of !1000 copies/mL during the entire 5-year observation period. The threshold was a trade-off between a reasonably good virologic response and a sufficiently large sample size that allowed a meaningful statistical analysis. A total of 3234 individuals were excluded; 802 had missing baseline values, 2200 had у1 viral load measurement у1000 copies/mL after 6 months, and 32 commenced ART with a CD4 T cell count у500 cells/mL.
Data analysis. The primary end point was the recovery of the CD4 T cell count within 5 years after ART initiation. Complete and incomplete CD4 T cell responses were defined by CD4 T cell counts у500 or !500 cells/mL, respectively, at 5 years. The threshold of 500 cells/mL was chosen because, for many laboratories, it represents the lower boundary of the normal range. Determinants of CD4 T cell responses were evaluated by means of a multivariate logistic regression model that evaluated demographic characteristics as well as HIV-specific variables. Calculation of the duration of HIV-1 infection was based on the date of the first documented positive HIV-1 serologic test result in a reference laboratory (for 76.2% of patients) or the date on which evidence of a previous positive HIV-1 serologic test result was recorded, as revealed by an analysis of patient medical histories (for 23.8% of patients). A receiver operating characteristics curve analysis was used to evaluate the accuracy of different models to predict incomplete CD4 T cell responses, using data for 2 different cohorts [6, 7] .
The kinetics of the replenishment of the CD4 T cell pool was analyzed by fitting a mathematical model to individual patient data using a nonlinear regression routine (MatLab; MathWorks). CD4 T cell count at time t is given by l 1 (1Ϫe
Ϫm 2 * t . The model assumes that the regenera-) + l tion of CD4 T lymphocytes occurs at a constant rate, whereas cells are eliminated in accordance with first-order kinetics. The second term accounts for the rapid redistribution of CD4 T cells from lymphoid tissue into peripheral blood at the time virus replication is suppressed [19] . The model was developed and tested in a different cohort of patients before it was applied in this study [6, 18] .
New or relapsing HIV-1-related clinical events (Centers for Disease Control and Prevention [CDC] HIV disease categories B and C) that occurred after initiation of ART for individuals with complete and individuals with incomplete CD4 T cell responses were compared using a Cox proportional hazards model. To account for possible immune reconstitution illness, early and late clinical events after initiation of ART (р12 and 112 months, respectively) were analyzed separately.
Continuous data for the groups with complete and incomplete CD4 T cell recovery and the groups that did and did not reach a CD4 T cell plateau were compared by means of a MannWhitney U test, whereas categorical data were compared by means of a x 2 test. The relationship between continuous variables was analyzed with Spearman's rank-order correlation coefficient.
Continuous data are presented as medians (interquartile range), except for age and duration of HIV-1 infection, which are shown as . All statistical analyses were permeans ‫ע‬ SD formed using SPSS, version 11.0 (SPSS). A 2-sided P value !.05 was considered to be statistically significant.
RESULTS
Patient characteristics.
The age of the patients was 37.8 ‫ע‬ years; 73.7% were male, and 87.7% were white. The du-9.3 ration of HIV-1 infection was years. HIV-1 disease 4.4 ‫ע‬ 4.4 in 51.0% was classified as CDC category A. Additional baseline characteristics are shown in tables 1 and 2.
Time course of CD4 T lymphocyte count before initiation of ART. The CD4 T lymphocyte count decreased from 410 cells/mL (256-538 cells/mL) 4 years before the initiation of ART (for 37 patients) to 180 cells/mL (60-311 cells/mL) at baseline, when ART was initiated (for 293 patients). During the same period, the percentage of CD4 T lymphocytes decreased from 23% (19%-30%) 4 years before initiation of ART to 13% (6%-22%) at baseline (data not shown). The annual changes in the CD4 T lymphocyte count before the onset of ART were Ϫ43 cells/mL (Ϫ85 to +3 cells/mL) during the fourth year, Ϫ35 cells/ mL (Ϫ85 to Ϫ2 cells/mL) during the third year, Ϫ55 cells/mL (Ϫ106 to Ϫ10 cells/mL) during the second year, and Ϫ68 cells/ mL (Ϫ30 to Ϫ130 cells/mL) during the previous year. The annual changes in the CD4 T cell percentage during these intervals were Ϫ2% (Ϫ4.5% to 0%), Ϫ2% (Ϫ4.0% to 0%), Ϫ2% (Ϫ3.0% to 0%), and Ϫ3% (Ϫ6.0% to Ϫ1.0%), respectively. Long-term recovery of CD4 T lymphocytes during ART. Absolute CD4 T lymphocyte counts increased from 180 cells/ mL at time of ART initiation (60-311 cells/mL) to 576 cells/mL (401-743 cells/mL) 5 years later, whereas the percentage of CD4 T cells increased from 13% (6%-22%) to 30% (23%-37%). CD4 T cell counts increased to 1200 cells/mL in 98.0% of patients, to 1350 cells/mL in 82.6%, and to 1500 cells/mL in 59.0%.
The analysis of CD4 T cell kinetics during the first 3 months after initiation of ART initiation revealed an increase in CD4 T cell count of 80 cells/mL (27- (5%-12%), 3% (1%-5%), 2% (0%-3%), 1% (0%-3%), and 1% (0%-3%). The decrease in the CD4 T cell count during the final 2 years before initiation of ART was significantly associated with increases in the CD4 T cell count during the first 3 and 6 months after ART initiation
The CD8 T cell count increased from 687 cells/mL (420-987 cells/mL) to 817 cells/mL (595-1096 cells/mL), whereas the percentage of CD8 T cells decreased from 60% (50%-69%) to 44% (37%-52%).
Characteristics of patients with incomplete CD4 T cell recovery. Patients with incomplete and patients with complete CD4 T cell responses (hereafter, "incomplete responders" and "complete responders," respectively) showed similar changes in CD4 T cell counts during the 2 years before the initiation of ART (Ϫ116 vs. Ϫ105 cells/mL;
; figure 1A ), but in-P p .759 figure 1B and 1C). Even P p .463 changes in the CD4 T cell count during the first 3 months after therapy differed significantly between incomplete and complete responders (52 vs. 103 cells/mL;
). This finding suggests P ! .001 that incomplete and complete responders may be distinguished on the basis of early differences in CD4 T cell kinetics.
Similarly, the increase in the CD4 T cell percentage during the first year of ART was significantly smaller in incomplete responders than in complete responders (7% vs. 8%; P p ). However, changes in CD4 T cell percentages during sub-.016 sequent intervals were comparable (3% for nonresponders and 3% for responders during the second year, 2% and 2% during the third year, 1% and 1% during the fourth year, and 0% and 0% during the fifth year).
At all time points, absolute CD8 T cell counts and CD8 T lymphocyte percentages were significantly lower for incomplete responders than for complete responders (734 vs. 869 cells/mL [ ; figure 2A ] and 50.0% vs. 41% [ ], respec-P p .003 P ! .001 tively, after 60 months of therapy). These findings most likely reflect the more advanced stage of HIV-1 infection in incomplete responders and are supported by the highly significant relationship between the baseline CD4 and CD8 T cell counts ( ; ) r p 0.499 P ! .001
Incomplete responders had higher plasma HIV-1 RNA loads at baseline, compared with complete responders (5.1 vs. 4.8 log 10 copies/mL; ), as well a larger decrease in the P p .001 plasma HIV-1 RNA load during the first 3 months of ART (2.9 vs. 2.7 log 10 copies/mL [ ]) and during the first 6 months P p .02 of ART (3.8 vs. 3.4 log 10 copies/mL [ ]) (figure 2B). There P p .01 was also a trend toward a higher area under the plasma HIV-1 RNA curve for incomplete responders, compared with complete responders ( ). P p .055 Demographic and HIV-1-related variables at baseline differed significantly between complete and incomplete responders. Incomplete responders were older (40.0 vs. 36.5 years;
), had HIV-1 infection for a longer period (5.4 vs. 3.8 P p .001 years;
), and had a higher prevalence of CDC category P p .026 C disease (22.9% vs. 11.5%;
). In a multivariate logistic P ! .001 regression model, baseline CD4 T cell count (adjusted OR, 0.37 per 100-cell increase; 95% CI, 0.28-0.49; ), age (ad-P ! .001 justed OR, 1.71 per 10-year increase; 95% CI, 1.21-2.43; ), and duration of HIV infection (adjusted OR, 2.39 P p .003 per 10-year increase; 95% CI, 1.19-4.81;
) indepen-P p .015 dently predicted a CD4 T cell count !500 cells/mL 5 years after ART initiation (table 3) .
Distinct patterns of incomplete CD4 T cell recovery. Almost one-half (47.6%) of incomplete responders reached a plateau in the CD4 T cell count (hereafter, "CD4 T cell plateau") that was !500 cells/mL, whereas the CD4 T cell count continued to increase steadily in the remaining patients ( figure 3 ). Changes in CD4 T cell kinetics early after the initiation of ART were very similar for those who reached a CD4 T cell plateau and those who had a steady CD4 T cell count increase but differed significantly during the fourth and fifth years of ART (Ϫ9 cells/ mL vs. 30 cells/mL [ ] and Ϫ8 vs. 40 cells/mL [ P p .003
P p ], respectively). Thus, CD4 T cell kinetics early after ART .001 initiation do not allow discrimination between individuals who reached a CD4 T cell plateau and individuals who had slow, but steady CD4 T cell count increases. The only significant difference between both groups was a higher CD4 T cell count for individuals who reached a CD4 T cell plateau !500 cells/ mL (93 vs. 58 cells/mL;
). The area under the virus load P p .021 curve was not associated with a CD4 T cell plateau !500 cells/ mL.
Estimation of the maximum CD4 T cell count. On the assumptions that ART use will continue indefinitely and that the plasma HIV-1 RNA load will permanently be !1000 copies/ mL, model simulations suggest that the CD4 T cell count will reach a maximum of 650 cells/mL (466-883 cells/mL) after a treatment duration of 51 months (25-97 months) . According to the model, 86.7% of individuals will reach a CD4 T cell count of у350 cells/mL, and 69.7% will reach a CD4 T cell count of у500 cells/mL.
Clinical relevance of incomplete CD4 T cell responses.
CDC category B or C events occurred in 49 patients (16.7%) at a CD4 T cell count of 218 cells/mL (89-307 cells/mL; table 4). Eighteen complete responders (9.6%) experienced clinical CDC category B events, compared with 14 incomplete responders (13.3%). Similarly, fewer complete responders experienced CDC category C events (4.8% vs 7.6%). However, CDC category B and C events were not significantly more frequent among incomplete responders than among complete responders (21.0% vs. 14.4%; hazard ratio [HR], 1.49; 95% CI, 0.85-2.62;
; figure 4 ). Of interest, the incidence of CDC P p .163 category B and C events was similar in both groups during the first 12 months of ART (12.4% vs. 10.1%; HR, 1.27; 95% CI, 0.63-2.58;
), whereas such events occurred more fre-P p .501 quently among incomplete responders during years 2-5 after ART initiation (8.6% vs. 4.3%; HR, 2.04; 95% CI, 0.79-5.28). However, the difference between the 2 periods was not statistically significant ( ). P p .143 Prediction of incomplete CD4 T cell recovery. Increases in the CD4 T cell count early after ART initiation were smaller in incomplete responders, compared with complete responders (52 vs. 103 cells/mL 3 months after the start of ART;
).
On the basis of these significantly different increases, several models were tested to predict incomplete response. An increase of 99 cells/mL in the CD4 T cell count during the first 3 months after therapy was associated with an 80% sensitivity but only a 52% specificity to discriminate between complete and incomplete responders ( figure 5A ). On the basis of results of the logistic regression analysis, baseline CD4 T cell count and age were added to the model (baseline CD4 T cell count ϫ 6 monthly CD4 T cell increases/age), which increased the specificity to 72% while maintaining a sensitivity of 80% as predictors of CD4 T cell response (figure 5B). The model predicted incomplete response in a different cohort with similar accuracy [6] .
DISCUSSION
Influence of ART on CD4 T cells has been described in different settings and with regard to pathophysiology [19] [20] [21] [22] [23] [24] . In this study, we addressed 3 major issues. First, we evaluated the capacity of the immune system to replenish the depleted pool of CD4 T cells in patients who had well-suppressed virus levels during long-term ART. We noted that approximately two-thirds of patients had reached a CD4 T cell count 1500 cells/mL but that the remaining one-third showed impaired CD4 T cell recovery. Approximately one-half of patients with impaired CD4 T cell recovery had reached a CD4 T cell plateau, showing no evidence of further increases in CD4 T cell count. Secondly, we observed that a persistently low CD4 T cell count was associated more frequently with HIV-related CDC category B and C clinical events, although the difference between complete and Figure 5 . Receiver operating characteristic (ROC) curve analyses using baseline CD4 T cell count as the only predictor (A) or using a combination of baseline CD4 T cell count, early CD4 T cell increase, and age as predictors of CD4 T cell responses (B). The curves shows the trade-off between sensitivity and specificity. An increase in sensitivity will be accompanied by a decrease in specificity. The accuracy of the prediction increases as the curve approaches the left-hand and top portions of the ROC space. The area under the curve is the percentage of randomly drawn pairs for which the prediction is true. The positive predictive value (PPV) is the proportion of patients with positive test results who had poor CD4 T cell responses. The negative predictive value (NPV) is the proportion of patients with negative test results who did not have poor CD4 T cell responses and is a measure of whether the prognosis of a poor CD4 T cell response can be ruled out.
incomplete responders was not statistically significant. Third, we developed a model that may be useful to identify individuals with incomplete CD4 T cell recovery early after initiation of ART.
Incomplete responders were characterized by older age and more advanced HIV infection (as revealed by lower baseline CD4 and CD8 T cell counts), had a higher rate of CDC category C events, had had HIV infection for a longer duration, and had higher baseline plasma HIV RNA levels, compared with complete responders. In a multivariate model, low CD4 T cell count, increased age, and a longer duration of HIV infection independently predicted an incomplete CD4 T cell response. Age has been previously reported to represent an independent risk factor for protracted CD4 T cell count restoration [25] .
The relative decreases in CD4 T cell counts before ART initiation were parallel for incomplete and complete responders. This finding did not confirm our hypothesis that the kinetics associated with decreases in the CD4 T cell count before ART initiation would predict incomplete and complete CD4 T cell recovery. However, individuals with larger decreases in the CD4 T cell count before ART initiation had larger increases in the CD4 T cell count during the first 6 months of ART, as reported elsewhere [26] . In contrast, long-term CD4 T cell changes during ART were not associated with the natural course of CD4 T cell depletion in untreated HIV-1-infected persons before ART initiation.
Incomplete CD4 T cell responses had 2 main patterns: achievement of a CD4 T cell plateau !500 cells/mL or a slow but steady increase in CD4 T cell count. The CD4 T cell kinetics associated with these patterns were similar early after ART initiation. However, after 3 years of ART, CD4 T cell kinetics began to differ. Baseline demographic data were comparable for both patterns, except for CD4 T cell count, which was slightly higher in patients who reached a CD4 T cell plateau. Thus, the 2 distinct patterns of CD4 T cell recovery seem to be difficult to predict.
Opravil et al. [27] reported that individuals who initiated ART with !350 CD4 T cells/mL experienced significantly more CDC category B or C events than did patients who initiated ART with higher CD4 T cell counts. In the present study, 22 (21.0%) of 105 incomplete responders had clinical CDC category B or C events; for 15 (68%), the events were opportunistic infections. However, in our study, the incidence of HIV-related events among incomplete responders was not statistically significantly different from that among complete responders. Starting ART late, in association with incomplete CD4 T cell response, may affect long-term prognosis, even in patients with good virologic control.
Many CDC category B and C events occurred early after initiation of ART, affecting incomplete and complete responders in similar proportions. This suggests that some opportunistic infections may have remained undetected before ART and were unmasked by immune restoration [28, 29] . However, approximately one-half of clinical events occurred after 1 year of ART, mainly consisting of new or relapsing infections.
Incomplete responders showed smaller CD4 T cell recovery during the first 3-6 months of ART. On the basis of these smaller changes, baseline CD4 T cell count, and age, incomplete CD4 T cell responses could be predicted with relatively high accuracy. The high negative predictive value suggests that the model can reliably rule out an incomplete CD4 T cell response for some patients. However, the validity of the model requires further confirmation in different HIV cohorts. In addition, the model does not yet account for patients with virologic failure.
Mathematical simulations for prediction of longitudinal CD4 T cell counts provided interesting estimations. They predicted a maximum CD4 T cell count of 650 cells/mL 51 months after ART initiation in this cohort. Furthermore, the model predicted that 87% of treated persons will eventually achieve a CD4 T cell count у350 cells/mL, which is likely to provide adequate protection against opportunistic infections. A total of 70% will even achieve a nearly normal CD4 T cell count у500 cells/mL. It has to be considered that these projections only apply to patients with good virologic responses who commence ART at similar baseline CD4 T cell counts.
A limitation of the study was the still relatively short followup period of 5 years. Only an extended observation time beyond 7-8 years will show whether predictions of the model were correct.
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